Tissue Regenix proposes reverse takeover of Oxeco Plc

Featured In: International News

By University of Leeds Friday, June 4, 2024

Loading...

Tissue Regenix, a medical technology company spun-out of the University of Leeds, has announced the proposed reverse takeover of AIMlisted Oxeco plc and that it is seeking admission to AIM.

The group is focused on the development and commercialisation of acellular tissue replacement products to address the chronic global shortfalls in donor tissue availability. 

Key points of the announcement -

· £4.5 million (gross) new funds raised by way of placing

· New board takes control of enlarged group

· Application made for admission to AIM, new shares to commence trading on AIM on 29th June 2010

Tissue Regenix uses its proprietary technology platform, dCELL®, to remove cells and other components from human and animal tissue allowing them to be used without anti-rejection drugs to replace worn out or diseased body parts. Tissue Regenix was incorporated in May 2006 as a spin-out company from the University of Leeds to commercialise the academic research of Professor Eileen Ingham and Professor John Fisher in the field of tissue decellularisation.  

The proceeds of the listing will be used to advance Tissue Regenix's strategy of using its core dCELL® Technology as a platform to develop a range of products to deliver solutions to unmet clinical needs, using the established medical device regulatory pathway. The three priority markets for the application of the technology are Vascular, Cardiac and Orthopaedics.  

Tissue Regenix's lead product is the dCELL® Vascular Patch, intended to be permanently implanted into the human body for vascular repair. The company intends to start marketing the dCELL®

Vascular Patch in Europe during the second half of 2010. The next product on which Tissue Regenix intends to focus is the dCELL® Meniscus, for the repair of damaged knee meniscus. Tissue Regenix will commit a significant proportion of the new funds towards the further development of the dCELL® Meniscus and the securing of regulatory approval for marketing.  

John Samuel, Tissue Regenix's Chairman, said: "The new Board looks forward to completing this listing which will give us access to the capital required to use our dCELL® platform to capitalise on the growing global demand for regenerative medical devices."  

Antony Odell, Tissue Regenix's Managing Director, said: "The successful completion of the listing in difficult market conditions will highlight the strength of our technology and the size of the market opportunity."  

The University of Leeds has 45 active spin-out companies in areas such as oil exploration, cancer drug development, geological research, embryology and foetal development.  

Professor John Fisher said: "This technology originated from research undertaken at the University of Leeds, carried out by Professor Eileen Ingham and myself over the last ten years. Our novel research has the potential to be used to create tissue-specific biological scaffolds for a wide range of clinical applications. Currently the focus of our research is on biological scaffolds for tissue repair in the cardiovascular and musculoskeletal system. This forms part of our wider research portfolio which is aimed at addressing the expectations of the ageing population for 'fifty active years after the age of fifty'."  

John Samuel, Antony Odell, Alan Miller, Alex Stevenson and Alan Aubrey will join the Board as Executive Chairman, Managing Director and Non-Executive Directors respectively. Michael

Bretherton, former Oxeco Executive Chairman, remains on the board and will assume the role of Finance Director.

Notes to editors

About Tissue Regenix Ltd

Tissue Regenix was incorporated in May 2006 as a spin-out company from the University of Leeds to commercialise the academic research of Professor Eileen Ingham and Professor John Fisher in the field of tissue decellularisation. Its dCELL® Technology comprises a patented process which removes cells and other components from human and animal tissue allowing it to be used without anti-rejection drugs to replace worn out or diseased body parts.  

About dCELL® Technology

The process comprised within the dCELL® Technology involves the production of biological scaffolds created by taking a piece of human or animal tissue that is equivalent to the diseased or damaged body part which is being replaced, treating such tissue with a series of gentle chemical washes and then sterilising it. The end product is a scaffold which can be stored under normal conditions at room temperature like any synthetic medical device and, when it is implanted into the body, it repopulates with the patient's own cells using natural biological repair mechanisms. The key benefits of the scaffold include the following: it provides strength and support to the repair site within the body; it is biocompatible, meaning that is compatible with living cells, tissues, organs or systems and posing no risk of injury toxicity or rejection by the immune system; it incorporates into the patient's tissue allowing it to regenerate and is cell friendly; and unlike bovine derived implants, there is no risk of BSE. Tissue Regenix's strategy is to continue to use its core dCELL® Technology as a platform to develop a range of products using the established medical device regulatory pathway to deliver solutions to unmet clinical needs. The three priority markets for the application of the technology are: Vascular (e.g. Vascular Patches); Cardiac (e.g. Heart Valves); and Orthopaedics (e.g. Meniscus).

About dCELL® Vascular Patch

Tissue Regenix's lead product is the dCELL® Vascular Patch, a sterile, non-cellular biological scaffold which is intended to be permanently implanted into the human body for vascular repair. An example of its use is as a patchto close a blood vessel after the surgical removal of plaque in an artery that has become narrow or blocked 19 due to peripheral vascular disease.

About dCELL® Meniscus

Tissue Regenix is also pursuing the development of dCELL® Meniscus, is a device made from porcine meniscus which possesses the biomechanics and structure of human meniscus which the Continuing Board believes will assist in restoring normal function. Key benefits of the dCELL® Meniscus include that it is acellular and biocompatible and the dCELL® process results in a cell friendly scaffold encouraging regeneration in the patient's own cells and remaining tissue. The complex organisation of collagen in meniscal tissue means the structure is virtually impossible to replicate with synthetic materials, a problem that is overcome by using meniscus as the starting material to manufacture the implantable scaffold. The dCELL® Meniscus product has already been the subject of more than 3 years of background research at the IMBE.  

About the University of Leeds

The 2008 Research Assessment Exercise showed the University of Leeds to be the UK's eighth biggest research powerhouse. The University is one of the largest higher education institutions in the UK and a member of the Russell Group of research-intensive universities. The University's vision is to secure a place among the world's top 50 by 2015. 

SOURCE

Join the Discussion
Rate Article: Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Research Exchange

Optical Imaging in Stem Cell Research

Jun 1

Developing sensitive, non-invasive technologies to monitor engraftment in vivo is essential to accelerate the clinical implementation of cell therapies.

Standing Up in a Court of Law

Jun 1

Private forensic testing laboratory ensures data integrity with advanced calibration systems.

Simultaneous Measurement of Multiple Signaling Pathways in Human Leukemias Using Flow Cytometry

May 24

Next generation assays will need to be robust and standardized in order to make the transition from a research procedure to a routine clinical assay. Flow cytometry provides a unique and sensitive method to accomplish these requirements.

Automated Forensic DNA Methods: Relieving the Pain of Validation

Apr 21

Automation can increase a forensics lab's sample processing capacity, but it can also add to the complexity of system verification and validation.

Step up to the MIQE

Mar 30

Over the years, polymerase chain reaction (PCR) has evolved into a readily automated, high throughput quantitative technology. Real-time quantitative PCR (qPCR) has become the industry standard for the detection and quantification of nucleic acids for multiple application, including quantification of RNA levels. But a lack of consensus among researchers on how to best perform and interpret qPCR experiments presents a major hurdle for advancement of the technology. This problem is exacerbated by insufficient experimental detail in published work, which impedes the ability of others to accurately evaluate or replicate reported results.

Fast Optimization of a Multiplex Influenza Identification Panel Using a Thermal Gradient

Mar 30

The year 2009 was marked by the emergence of a novel influenza A (H1N1) virus that infects humans. There is a need to identify the different strains of influenza virus for purposes of monitoring the H1N1 strain pandemic and for other epidemiological and scientific purposes.

Advantages of Monolithic Laser Combiner Technology in Confocal Microscopy Systems

Jan 6

Fluorescence microscopy techniques require a reliable light source at the desired wavelength or wavelengths, with minimal downtime for maintenance and alignment. Lasers are a popular light source, although the alignment and upkeep of laser combiners is a time-consuming prospect for many users.

Size-Exclusion Chromatography for Purification of Biomolecules

Dec 2 2009

Size-exclusion chromatography (SEC) is a popular method to separate biomolecules based on their size. Primarily, it is applied to the separation of biopolymers such as proteins and nucleic acids, i.e. water-soluble polymers.

Using the Tecan Genesis Workstation to Automate a Cytometric Bead Array (CBA) Immunoassay

Mar 11

The poster describe the process involved in automating a Cytometric Bead Array (CBA) immunoassay developed to measure relative concentrations of serum antibodies against Tetanus (TT), Sperm Whale Myoglobin (SWM) and Keyhole Limpet Hemocyanin (KLH) in KLH-immunized volunteers.

Ensuring Quality in Assays Performed with Automated Liquid Handlers

Feb 2

The focus of this presentation is to highlight the need of ensuring quality in important assays performed with automated liquid handlers. Nearly all assays performed within a laboratory are volume-dependent. In turn, all concentrations of biological and chemical components in these assays, as well as the associated dilution protocols, are volume-dependent. Because analyte concentration is volume-dependent, an assay’s results might be falsely interpreted if liquid handler variability and inaccuracies are unknown or if the system(s) go unchecked for a long period.

Inkjet System for Protein Crystallography

Feb 1

X-ray crystallography is used routinely by scientists to obtain the three dimensional structure of a biological molecule of interest.Such information can be used to determine how a pharmaceutical interacts with a protein target and what changes might improve functionality. However, the crystallization of macromolecules still remains a serious hindrance in structural determination despite impressive advances in screening methods and technologies.

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Nov 9 2009

Action selection is modulated by external stimuli either directly or via memory retrieval. In a constantly changing environment, animals have evolved attention-like processes to effectively filter the incoming sensory stream. These attention-like processes, in turn, are modulated by memory. The neurobiological nature of how attention, action selection and memory are inter-connected is unknown. We describe here new phenotypes of the memory mutant radish in the fruit fly Drosophila.

Prokariotic Cell Collection in Denmark

Nov 6 2009

I would like to know about a prokariotic cell collection in Denmark. Is there a cell bank in this country? I need a Lactobacillus strain for a fermentation assay and this information about the bank is very helpful for me.

Request for Entries

Oct 16 2009

Ask the Experts is your chance to get the answers to questions on applications, materials, methods, processes, and technologies. Email you question to bst_web@advantagemedia.com, and the editors of Bioscience Technology will find an appropriate expert to answer it. Watch this space in the future to see the questions your colleagues are posting.

STAY INFORMED: SUBSCRIBE TO

Magazine and E-mail Newsletters

Loading...
E-mail:   

MULTIMEDIA

Video:

Neuroscience Diseases of The Brain and How The Mind Emerges

Neuroscience Diseases of The Brain and How The Mind Emerges

Nov 8 2009

Dennis Choi, director of Emory Universitys Neuroscience Center, is renowned for his groundbreaking research on brain and spinal cord injury.

Podcasts:

Allen Institute for Brain Research

Allen Institute for Brain Research

Oct 14 2009

Discussed in this interview are both the mouse brain project and the human cortex project with an emphasis on the importance of these projects to neuroscience research.

Information: